[8] Frey is a pioneer in the development of machine learning and artificial intelligence methods, their use in accurately determining the consequences of genetic mutations, and in designing medications that can slow, stop or reverse the progression of disease.
He was an invited participant of the Machine Learning program at the Isaac Newton Institute for Mathematical Sciences in Cambridge, UK (1997) and was a Beckman Fellow at the University of Illinois at Urbana Champaign (1999).
Frey’s group pioneered much of the early work in the field and over the next 15 years published more papers in leading-edge journals than any other academic or industrial research lab.
In 2015, Frey founded Deep Genomics, with the goal of building a company that can produce effective and safe genetic medicines more rapidly and with a higher rate of success than was previously possible.
[10][11][12] The company has received 240 million dollars in funding to date from leading Bay Area investors, including the backers of SpaceX and Tesla.